PERRIGO CO PLC's ticker is PRGO and the CUSIP is G97822103. A total of 336 filers reported holding PERRIGO CO PLC in Q3 2020. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About PERRIGO CO PLC
Perrigo Co PLC is a leading global healthcare supplier that specializes in the production of over-the-counter (OTC) and prescription medications, as well as nutritional products and active pharmaceutical ingredients. The company has a strong presence in the United States, Europe, and Australia, and is committed to providing high-quality, affordable healthcare products to consumers around the world.
Perrigo's success can be attributed to its focus on innovation and customer satisfaction. The company invests heavily in research and development to create new and improved products that meet the evolving needs of its customers. Additionally, Perrigo places a strong emphasis on customer service, ensuring that its products are readily available and easy to use.
One of Perrigo's key strengths is its diverse product portfolio. The company offers a wide range of healthcare products, including allergy medications, pain relievers, vitamins, and infant formula. This diversity allows Perrigo to weather fluctuations in demand for any one product, and ensures that the company remains a reliable supplier of healthcare products.
Despite the challenges posed by the COVID-19 pandemic, Perrigo has continued to perform well. The company's strong financial position and commitment to innovation have allowed it to adapt to changing market conditions and continue to provide high-quality healthcare products to consumers around the world.
Overall, Perrigo Co PLC is a strong and reliable healthcare supplier that is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $469,122 | +37.6% | 18,268 | +72.4% | 0.01% | 0.0% |
| Q4 2023 | $340,979 | +30.6% | 10,596 | +37.7% | 0.01% | +33.3% |
| Q2 2023 | $261,177 | -49.3% | 7,693 | -49.1% | 0.01% | -14.3% |
| Q4 2022 | $514,760 | -16.6% | 15,100 | -12.7% | 0.01% | -41.7% |
| Q3 2022 | $617,000 | +124.4% | 17,290 | +141.8% | 0.01% | +140.0% |
| Q1 2022 | $275,000 | -66.9% | 7,150 | -60.6% | 0.01% | -75.0% |
| Q2 2021 | $832,000 | -35.0% | 18,157 | -42.6% | 0.02% | -59.2% |
| Q1 2021 | $1,280,000 | +352.3% | 31,634 | +517.9% | 0.05% | +188.2% |
| Q2 2020 | $283,000 | – | 5,120 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Starboard Value LP | 9,641,425 | $840,347,000 | 20.55% |
| Greenlight Capital | 2,836,632 | $247,241,000 | 4.49% |
| Moon Capital Management, LLC | 42,867 | $3,736,288,000 | 3.83% |
| SECTOR GAMMA AS | 249,540 | $21,750,000 | 3.66% |
| 13D Management LLC | 134,998 | $11,766,000 | 3.51% |
| Clal Insurance Enterprises Holdings Ltd | 1,436,621 | $125,216,000 | 3.30% |
| SASCO CAPITAL INC / CT/ | 1,015,092 | $88,475,000 | 3.24% |
| Ibex Investors LLC | 57,000 | $4,968,000 | 2.88% |
| Migdal Insurance & Financial Holdings Ltd. | 1,299,747 | $113,286,000 | 2.81% |
| Goodman Financial Corp | 60,465 | $5,270,000 | 2.38% |